21.74Open21.74Pre Close0 Volume10 Open Interest20.00Strike Price0.00Turnover147.23%IV6.29%PremiumJul 19, 2024Expiry Date19.27Intrinsic Value100Multiplier18DDays to Expiry2.47Extrinsic Value100Contract SizeAmericanOptions Type0.9856Delta0.0028Gamma2.02Leverage Ratio-0.0150Theta0.0100Rho1.99Eff Leverage0.0033Vega
Structure Therapeutics Stock Discussion
On fire
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
$Iovance Biotherapeutics(IOVA.US)$ Phase 2
$Supernus Pharmaceuticals(SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$ Phase 2a
$MorphoSys(MOR.US)$ Phase 2
$Nuvation Bio(NUVB.US)$ Phase 2
$ALX Oncology(ALXO.US)$ Phase 2
$BioXcel Therapeutics(BTAI.US)$ Phase 2
$Purple Biotech(PPBT.US)$ Phase 2
$Arcus Biosciences(RCUS.US)$ Phase 2
$Medicenna Therapeutics(MDNAF.US)$ Phase 2b
$Affimed NV(AFMD.US)$ Phase 2
$Barinthus Biotherapeutics(BRNS.US)$ Phase 2b...
JMP Securities Reiterates Market Outperform on Structure Therapeutics, Maintains $91 Price Target - moomoo
Obesity Drug - Update & Battle for Skinny
SubQ- $VKTX ph2 results puts the company in driver's seat after showing impressive results both in efficacy and safety
$VKTX has shown twice as much weight loss in 13 weeks what $LLY has done in 12 weeks and what $NVO has shown in 40 plus weeks
In safety, VKTX shown its superiority too vs LLY and NVO
For comparison...
No comment yet